Clinical trial
CC100: Phase 1 Multiple-Dose Safety and Tolerability in Subjects With ALS
NCT03049046
Study timeline
Study start (actual)2017-04-07Date precision: day
Registry last updated2017-08-03
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Amyotrophic Lateral Sclerosisunresolved
Interventions
Sponsors & collaborators
Chemigen, LLClead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03049046 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.